



Pascal Soriot
Chief Executive Officer

7th March, 2014

The Community Research Advisors Group (CRAG)
The Global TB Community Advisor Board (TB CAB)
Treatment Action Group (TAG)

C/O Erica Lessem, MPH
Assistant Director, TB/HIV Project
Treatment Action Group
261 Fifth Avenue, Suite 2110
New York, NY 10016 USA

Dear Ms. Lessem,

Thank you for your letter of February 13, 2014, in which you acknowledge AstraZeneca's contributions to the field of tuberculosis research and urge us to continue to invest in this important disease area.

Please be assured that we are committed to advancing our AZD5847 programme as quickly as possible and we continue to invest in this programme. The Phase IIa trial started in December 2012, just over a year ago, and enrolment and dosing were completed in December 2013. It is important to point out that the timelines of the trial are determined by the National Institute of Allergy and Infectious Diseases (NIAID), which is sponsoring this trial.

I would also like to address your assertion that funding was "cut" by AstraZeneca from 2011 to 2012. In drug discovery and development, costs vary from year to year as programmes advance. In the case of AZD5847, costs associated with the Phase I trial carried out in 2011 were higher than those associated with necessary research conducted in 2012 to characterise and establish the safety of the major metabolite of AZD5847 identified in Phase I.

While we are ceasing our in-house early-stage research programme in Neglected Tropical Diseases (NTD), tuberculosis and malaria, we will continue to share our compounds and expertise through open innovation partnerships. We believe this has significant value and is consistent with the spirit and letter of the London Declaration where, as detailed in the 2012 progress report, we provided more than 65,000 compounds in support of research into NTDs. Ongoing collaborations include projects in TB, malaria, and other NTDs. These are conducted in collaboration with a number of organisations including the TB Alliance, Liverpool School of Tropical Medicine and Drugs for Neglected Diseases initiatives.

The decision is consistent with our previously-announced strategy to focus our resources in our core therapy areas of oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity, while taking an opportunistic approach in infection and neuroscience.

We fully recognise that NTDs represent a significant unmet need which is why we continue to make our compounds and expertise available to researchers working in this area. We believe that tackling these diseases is a responsibility shared by many parties including governments, NGOs and business. By collaborating in the discovery, development and the distribution of much-needed medicines we stand the best chance of benefiting patients.

Yours sincerely

A handwritten signature in black ink, appearing to read "P. Soriot", is placed below the text "Yours sincerely".

Pascal Soriot

Cc Mene Pangalos, Briggs Morrison, Paul Hudson, Manos Perros, Scott Butler